Published in N Engl J Med on November 27, 2008
Network medicine: a network-based approach to human disease. Nat Rev Genet (2011) 14.07
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol (2002) 5.15
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med (2010) 2.62
miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J (2010) 2.47
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood (2009) 2.43
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 2.42
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell (2016) 2.10
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat Genet (2012) 2.02
Supervised group Lasso with applications to microarray data analysis. BMC Bioinformatics (2007) 1.99
Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell (2012) 1.98
Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood (2010) 1.77
Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia (2009) 1.77
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol (2015) 1.73
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood (2012) 1.68
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood (2014) 1.66
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
Variable selection for optimal treatment decision. Stat Methods Med Res (2011) 1.61
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell (2012) 1.54
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma (2013) 1.51
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood (2015) 1.51
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood (2015) 1.51
A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One (2013) 1.50
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood (2013) 1.48
DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med (2015) 1.48
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med (2011) 1.45
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood (2016) 1.45
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One (2012) 1.42
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Additive risk survival model with microarray data. BMC Bioinformatics (2007) 1.40
A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn (2010) 1.37
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood (2008) 1.36
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res (2011) 1.30
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood (2009) 1.28
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J (2012) 1.26
Drug repositioning for personalized medicine. Genome Med (2012) 1.24
Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer (2012) 1.23
Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer (2011) 1.22
Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol (2012) 1.20
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica (2013) 1.19
Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A (2012) 1.19
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med (2010) 1.19
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med (2013) 1.16
The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica (2011) 1.15
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica (2009) 1.15
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget (2015) 1.15
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget (2014) 1.13
Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A (2013) 1.13
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res (2013) 1.12
The NF-κB genomic landscape in lymphoblastoid B cells. Cell Rep (2014) 1.12
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol (2014) 1.12
MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res (2011) 1.12
Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol (2011) 1.11
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest (2012) 1.09
Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol (2011) 1.07
Adaptive index models for marker-based risk stratification. Biostatistics (2010) 1.07
Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood (2012) 1.03
Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol (2012) 1.03
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica (2010) 1.03
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol (1986) 18.40
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A (2001) 11.06
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA (2001) 10.63
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med (2001) 7.14
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2001) 6.66
Isolation of a protein that is essential for the first step of nuclear protein import. Cell (1994) 6.63
Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science (1997) 6.58
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
The vagus influences giving rise to the phenomena accompanying expansion and collapse of the lungs. J Physiol (1932) 5.96
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Human leukocyte interferon produced by E. coli is biologically active. Nature (1980) 5.86
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000) 5.43
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29
New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol (1998) 4.92
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature (1990) 4.69
Random genetic drift in the female germline explains the rapid segregation of mammalian mitochondrial DNA. Nat Genet (1996) 4.68
Chronic lymphocytic leukemia. N Engl J Med (1995) 4.52
Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol (1995) 4.46
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
A novel class of RanGTP binding proteins. J Cell Biol (1997) 4.36
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Distinct functions for the two importin subunits in nuclear protein import. Nature (1995) 4.16
The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med (2001) 4.12
Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura. Lancet (1997) 4.09
Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol (2001) 4.09
Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol (1992) 4.04
Identification of a tRNA-specific nuclear export receptor. Mol Cell (1998) 3.94
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet (1998) 3.79
A mammalian homolog of SEC61p and SECYp is associated with ribosomes and nascent polypeptides during translocation. Cell (1992) 3.78
The synaptic SNARE complex is a parallel four-stranded helical bundle. Nat Struct Biol (1998) 3.74
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
Signatures of the immune response. Immunity (2001) 3.66
A 41 amino acid motif in importin-alpha confers binding to importin-beta and hence transit into the nucleus. EMBO J (1996) 3.65
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Light control of Arabidopsis development entails coordinated regulation of genome expression and cellular pathways. Plant Cell (2001) 3.60
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys (2000) 3.47
Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature (1997) 3.47
Posttranslational protein transport in yeast reconstituted with a purified complex of Sec proteins and Kar2p. Cell (1995) 3.46
Undergraduate research. Genomics Education Partnership. Science (2008) 3.45
beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene (2006) 3.43
A piston model for transmembrane signaling of the aspartate receptor. Science (1999) 3.42
Mapping of contralateral space in retinotopic coordinates by a parietal cortical area in humans. Science (2001) 3.41
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Spiral Tube Assembly for High-Speed Countercurrent Chromatography: Choice of Elution Modes for Four Typical Two-Phase Solvent Systems. J Liq Chromatogr Relat Technol (2008) 3.33
Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol (2000) 3.27
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol (1998) 3.21
A protein of the endoplasmic reticulum involved early in polypeptide translocation. Nature (1992) 3.20
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation (1987) 3.16
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol (1990) 3.14
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med (1997) 3.12
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane. EMBO J (1995) 2.96
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 2.95